(Total Views: 271)
Posted On: 01/27/2022 9:28:23 PM
Post# of 1418
That definitely is just market opportunity. Here's the crazy part. Todos doesn't even need it to be successful
Given all the stuff that was approved or that people want to use...
- remdesivir, ivermectin, hydroxychloroquine, chloroquine, monoclonal antibody treatments – bamlanivimab and etesevimab (administered together) and REGEN-COV (casirivimab and imdevimab)
That once worked, never worked, sorta works sometimes, it shows the market demand for just about anything that has a story attached to it, as people unfortunately are desperate.
I imagine once the story gets out about Tollovid, that it actually worked in two different studies and you can actually buy it today, the market might go nuts for Tollovid.
I can imagine sales potentially doubling each month for Tollovid. I'm sure Todos is thinking it. We'll see what happens. Then add into that what Gerald mentioned of Tollovid being the base and that they can add other things to. Also the potential for Tollovid one day being over the counter like Zicam or other pills. I posted Zicam sold in 2020 for over half a billion.
The positive data from this small trial today with the hardest setting (hospitalized) is a marketing gold mine for Tollovid. Everyone I know that I suggested taking Tollovid, I want back today and said, see the news today.
Now a question for Todos would be, how many bottles can you produce in 2022 and what are the margins. We know the margins of testing today which was great to hear.
Can they product 100M bottles?
100M @ $50 = $5B
But lets take 1M bottles that should be easily doable
1M @ $50 = Todos Market Cap
That isn't even the Max and that doesn't include any of the other revenue
The challenge for Todos is, they have so many avenues to go down, which ones to you pick first. I guess it depends on expansion of compassionate use and emergency use approval in a few countries. Each use/approval will have a greater acceleration of Tollovid sales in my view but what do I know. I'm the guy that bought at the HOD and close to LOD today.
Given all the stuff that was approved or that people want to use...
- remdesivir, ivermectin, hydroxychloroquine, chloroquine, monoclonal antibody treatments – bamlanivimab and etesevimab (administered together) and REGEN-COV (casirivimab and imdevimab)
That once worked, never worked, sorta works sometimes, it shows the market demand for just about anything that has a story attached to it, as people unfortunately are desperate.
I imagine once the story gets out about Tollovid, that it actually worked in two different studies and you can actually buy it today, the market might go nuts for Tollovid.
I can imagine sales potentially doubling each month for Tollovid. I'm sure Todos is thinking it. We'll see what happens. Then add into that what Gerald mentioned of Tollovid being the base and that they can add other things to. Also the potential for Tollovid one day being over the counter like Zicam or other pills. I posted Zicam sold in 2020 for over half a billion.
The positive data from this small trial today with the hardest setting (hospitalized) is a marketing gold mine for Tollovid. Everyone I know that I suggested taking Tollovid, I want back today and said, see the news today.
Now a question for Todos would be, how many bottles can you produce in 2022 and what are the margins. We know the margins of testing today which was great to hear.
Can they product 100M bottles?
100M @ $50 = $5B
But lets take 1M bottles that should be easily doable
1M @ $50 = Todos Market Cap
That isn't even the Max and that doesn't include any of the other revenue
The challenge for Todos is, they have so many avenues to go down, which ones to you pick first. I guess it depends on expansion of compassionate use and emergency use approval in a few countries. Each use/approval will have a greater acceleration of Tollovid sales in my view but what do I know. I'm the guy that bought at the HOD and close to LOD today.
(1)
(0)
